Incyte Corporation vs MakeMyTrip Ltd — how do they compare? Incyte Corporation trades at $116 (market cap $23.44B), while MakeMyTrip Ltd trades at $52.67 (market cap $5.36B). The key difference: Incyte Corporation is far larger — about 4.4× MakeMyTrip Ltd's market cap, and Incyte Corporation is trading nearer its 52-week high, MakeMyTrip Ltd nearer its low. Which is the better fit depends on your goals.
| INCY | MMYT | |
|---|---|---|
Market Cap | $23.44B | $5.36B |
Sector | Health | Technology |
52-Week High | $118.52 | $103.21 |
52-Week Low | $68.90 | $36.30 |
Enterprise Value | $19.46B | $6.00B |
Trailing returns across standard periods
Latest headlines on both assets
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →MakeMyTrip Ltd. is a leading online travel company in India, providing a comprehensive range of travel services and products, including air tickets, hotels, holiday packages, rail tickets, and bus tickets. The company operates its primary websites and mobile apps under the brands MakeMyTrip, Goibibo, and RedBus. MMYT serves as a key intermediary in India's fragmented travel market, leveraging its platform to offer convenience and competitive pricing to consumers and businesses.
Read more on MMYT →